The content on this site is intended for healthcare professionals only
Afatinib delays progression of advanced lung adenocarcinomas
Routine molecular testing of non-small cell lung cancers in community settings
Increased progression-free survival in advanced lung cancer with afatinib
Early results from new PD-1 targeted immune therapy
EGFR mutation unique to glioblastoma linked to lack of response
Use of neutrophils to prevent lung metastases in breast cancer patients
Antiangiogenic therapies for non-small cell lung cancer
Cellular pathways in lung cancer and the need for personalised medicine
The evolving role of immunotherapy in oncology
Latest in renal carcinoma
Use of circulating tumour cells as a prognostic or predictive marker
Message from the President-Elect of ESTRO
